PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?

The standard of care for newly diagnosed advanced ovarian cancer (NADOC) is represented by surgical debulking followed by systemic platinum–taxanes combination chemotherapy. At the last European Society for Medical Oncology (ESMO) Congress, results from three trials testing three different poly-aden...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Franzese, Elisena, Diana, Anna, Centonze, Sara, Pignata, Sandro, De Vita, Ferdinando, Ciardiello, Fortunato, Orditura, Michele
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7303974/
https://ncbi.nlm.nih.gov/pubmed/32596142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00782
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados